Literature DB >> 3783079

Synthetic antagonists of the myometrial response to vasopressin and oxytocin.

P Melin, J Trojnar, B Johansson, H Vilhardt, M Akerlund.   

Abstract

With the aim of developing inhibitors of vasopressin- and oxytocin-induced uterine activity, 17 analogues of 1-deamino-oxytocin were synthesized by the solid-phase method. Modifications were made at positions 2, O-methyltyrosine (Tyr(OMe] and O-ethyltyrosine (Tyr(OEt],D-Tyr,D-Tyr(OEt),D-Trp; 4, Val,Thr and 8, Orn,Cit,Arg,D-Arg. The analogues were tested for antiuterotonic activity in vitro and in vivo in the rat and in vitro on myometrial strips from non-pregnant women and pregnant women at term. Their selectivity was also investigated in blood pressure and antidiuretic bioassays in rats. Results were compared with those from an original antiuterotonic analogue 1-deamino-2-Tyr(OEt)-oxytocin (d(OEt)-oxytocin). In the rat in vitro and in vivo all analogues possessed higher antiuterotonic activity than d(OEt)-oxytocin. The negative logarithm of the molar concentration of the antagonist which reduced the effect of a dose of agonist to that of half the dose (pA2) was between 7.6 and 8.9 for all the new inhibitors compared with 7.2 for d(OEt)-oxytocin. The highest pA2 value was found for 1-deamino-2-Tyr(OMe)-8-Orn-oxytocin (8.9 +/- 0.2, S.E.M.) and 1-deamino-2-Tyr(OEt)-4-Thr-8-Orn-oxytocin (8.9 +/- 0.6). In myometrium from non-pregnant women the most potent peptide was 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin (17.2 +/- 2.0 times more potent that d(OEt)-oxytocin). In myometrium from pregnant women the inhibitory effects of the majority of the analogues were less pronounced.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783079     DOI: 10.1677/joe.0.1110125

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  14 in total

1.  Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.

Authors:  A Tahara; J Tsukada; Y Tomura; K i Wada; T Kusayama; N Ishii; T Yatsu; W Uchida; A Tanaka
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 2.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Comparative study of eight oxytocin antagonists by simulated annealing.

Authors:  Balázs Jójárt; Arpád Márki
Journal:  J Mol Model       Date:  2006-03-07       Impact factor: 1.810

Review 4.  Trends in peptide drug discovery.

Authors:  Markus Muttenthaler; Glenn F King; David J Adams; Paul F Alewood
Journal:  Nat Rev Drug Discov       Date:  2021-02-03       Impact factor: 84.694

Review 5.  The physiological basis for administration of oxytocin antagonists in preterm labour.

Authors:  S Thornton; S K Smith
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

6.  Enhanced intestinal absorption of oxytocin peptide analogues in the absence of pancreatic juice in pigs.

Authors:  D P Lundin; S Lundin; H Olsson; B W Karlsson; B R Weström; S G Pierzynowski
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

Review 7.  Hormonal and local regulation of uterine activity during parturition: Part I--The oxytocin system.

Authors:  M Maggi; E Baldi; T Susini
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

8.  Oxytocin stimulates secretory processes in lactating rabbit mammary epithelial cells.

Authors:  Vanessa Lollivier; Pierre-Guy Marnet; Serge Delpal; Dominique Rainteau; Caroline Achard; Aline Rabot; Michèle Ollivier-Bousquet
Journal:  J Physiol       Date:  2005-09-15       Impact factor: 5.182

Review 9.  Atosiban for preterm labour.

Authors:  Vassilis Tsatsaris; Bruno Carbonne; Dominique Cabrol
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.